RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Breast Cancer Channel

subscribe to Breast Cancer newsletter
Latest Research : Cancer : Breast Cancer

   EMAIL   |   PRINT
Osteoporosis drug approved to cut breast cancer risk

Sep 15, 2007 - 1:39:48 PM
In addition, Evista should not be taken with cholestyramine - or estrogens.

 
[RxPG] In 1997, FDA approved Evista, which is manufactured by Eli Lilly and Company, for the prevention of osteoporosis in postmenopausal women and in 1999, for the treatment of osteoporosis in postmenopausal women.

Evista Friday became the second drug approved to reduce the risk of breast cancer. Evista is commonly referred to as a selective oestrogen receptor modulator -. In reducing the risk of invasive breast cancer, SERMs may act by blocking oestrogen receptors in the breast.

'Today's action provides an important new option for women at heightened risk of breast cancer,' Steven Galson, director of FDA's Centre for Drug Evaluation and Research, said Friday.

'Because Evista can cause serious side effects, the benefits and risks of taking Evista should be carefully evaluated for each individual woman,' he said.

The serious side effects include blood clots in the legs and lungs, and death due to stroke. Women with current or prior blood clots in the legs, lungs, or eyes should not take Evista. Other potential side effects include hot flashes, leg cramps, swelling of the legs and feet, flu-like symptoms, joint pain, and sweating.

Evista should not be taken by pre-menopausal women and women who are or may become pregnant because it may cause harm to the unborn baby, FDA warned in its statement.

In addition, Evista should not be taken with cholestyramine - or estrogens.

Evista does not completely prevent breast cancer. Breast examinations and mammograms should be done before starting Evista and regularly thereafter, said FDA.




Advertise in this space for $10 per month. Contact us today.


Related Breast Cancer News
Blood test predicts breast cancer recurrence
Interferon-stimulated gene 15 (ISG15), a ubiquitin like protein, is a new therapeutic target for breast cancer
Smoking may have an association with breast cancer in women
Vitamins and calcium supplements appear to reduce the risk of breast cancer
Acupuncture has added benefits in breast cancer patients
Study finds higher risk of cancer recurrence in women with dense breasts
Physical activity after menopause reduces breast cancer
Genes responsible for susceptibility to breast cancer metastasis can be inherited
Oestrogen therapy of benefit in some women with metastatic cancer
Awry protein linked to breast cancer

Subscribe to Breast Cancer Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)